Related Experiment Videos
Salvage chemotherapy for oligodendroglioma
K Peterson1, N Paleologos, P Forsyth
1Department of Neurology, University of Minnesota, Minneapolis, USA.
Journal of Neurosurgery
|October 1, 1996
Summary
Salvage chemotherapy with procarbazine, lomustine (CCNU), and vincristine (PCV) is effective for oligodendroglioma recurrence after non-PCV treatment. Etoposide (VP-16)/cisplatin (CDDP) also shows promise for recurrent brain tumors.
Area of Science:
- Neuro-oncology
- Medical oncology
- Brain tumor research
Background:
- Oligodendroglioma is an uncommon brain tumor.
- Initial chemotherapy with procarbazine, lomustine (CCNU), and vincristine (PCV) is predictably effective.
- Salvage chemotherapy is used for recurrent oligodendroglioma after initial treatment.
Purpose of the Study:
- To evaluate the effectiveness of salvage chemotherapy regimens for recurrent oligodendroglioma.
- To identify chemotherapy regimens that are effective when initial treatments fail.
Main Methods:
- Retrospective review of 23 patients with oligodendroglioma who received second, third, or fourth cytotoxic regimens.
- Analysis of treatment response based on measurable changes in tumor size.
- Comparison of outcomes based on prior chemotherapy regimens, specifically PCV and non-PCV agents.
Main Results:
- PCV was highly effective as salvage therapy (7/8 patients responded) when prior chemotherapy did not include PCV.
- PCV was ineffective when administered after prior PCV treatment.
- Etoposide (VP-16)/cisplatin (CDDP) showed a 40% response rate in patients previously treated with PCV.
Conclusions:
- PCV is a valuable salvage treatment for oligodendroglioma recurrence following non-PCV chemotherapy.
- The combination of etoposide (VP-16) and cisplatin (CDDP) demonstrates significant anti-oligodendroglioma activity and warrants further investigation.